CNR1 and post-traumatic stress disorder: Future research should, therefore, aim to clarify the acute effects of CB1 agonists vs. chronic use, as well as examining differences in effects among normal, healthy subjects vs. those at risk of having altered endocannabinoid activity (e.g., sufferers of PTSD).